Goldman Sachs is cutting jobs again amid Wall Street deals slump

Goldman Sachs is cutting jobs again amid Wall Street deals slump


David Solomon, CEO, Goldman Sachs, speaks during the Milken Institute Global Conference in Beverly Hills, California, April 29, 2019.

Kyle Grillot | Bloomberg | Getty Images

Goldman Sachs is preparing for its third round of layoffs since September as Wall Street firms adjust to a slump in deals activity.

The company is expected to trim fewer than 250 jobs in the coming weeks, a person with knowledge of the New York-based bank’s plans said Tuesday.

Goldman Sachs, led by CEO David Solomon, was among the first major Wall Street firms to trim jobs in September, cutting a few hundred positions. It then slashed more jobs in January, releasing about 3,200 employees. Morgan Stanley announced about 3,000 job cuts this month, and JPMorgan Chase cut about 500 jobs, CNBC reported last week.

But Goldman is more tied to the ups and downs of Wall Street than its rivals. Its combined 16% drop in first-quarter trading and advisory revenue contributed to a disappointing start to the year.

Managing directors and some partners will be affected by the Goldman cuts, according to the person, who declined to be identified speaking about layoffs. The Wall Street Journal reported the news earlier Tuesday.

Goldman had 45,400 employees as of March 31, a 6% decline from the fourth quarter of 2022.

Clarification: This story was updated to reflect that JPMorgan Chase had cut about 500 jobs last week.



Source

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Business

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight.  The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]

Read More
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More
Macy’s store revamp shows progress, but company expects sales to fall this year
Business

Macy’s store revamp shows progress, but company expects sales to fall this year

Macy’s on Wednesday beat Wall Street’s quarterly sales and profit expectations as its namesake brand showed signs of progress, yet still gave a cautious outlook for the year ahead. For the fiscal year, the company – which includes its namesake chain, higher-end department store Bloomingdale’s and beauty retailer Bluemercury – said it expects sales of […]

Read More